These latest presentations represent our ongoing efforts as a company to provide breakthrough methodologies for utilizing large data sets of patient records for outcomes studies and clinical trials recruitment.
Montreal, Quebec, Canada (PRWEB) August 28, 2013
Anolinx™, a pharmacoepidemiology and patient recruitment company headquartered in Salt Lake City Utah, made an impactful showing at the International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE), August 25-28, 2013, in Montreal, Canada, by presenting eight posters. The peer reviewed presentations demonstrate Anolinx’s ongoing leadership in utilizing electronic health records to analyze cohorts and identify patients with greater precision and specificity.
Dr. Aaron Kamauu, MD MS MPH, Anolinx™ CEO and a recognized leader in health informatics and epidemiology, said that “these latest presentations represent our ongoing efforts as a company to provide breakthrough methodologies for utilizing large data sets of patient records for outcomes studies and clinical trials recruitment.
Collaborating with pharmaceutical industrial leaders, the U.S. Department of Veterans Affairs and The University of Utah School of Medicine, Anolinx™ researchers produced posters on topics ranging from novel techniques in patient identification to methods of unearthing the dynamic structure of large healthcare data systems.”
According to Senior Vice President, Justin Spencer, “Anolinx™ is on the cutting edge of real world evidence. “The fact that eight of our posters were accepted for this conference is a testament to the innovation occurring at Anolinx. That innovation is powered by world-class analytics and our unique and robust data network.”
The titles for the posters being presented this week are:
1. Using Natural Language Processing to Identify US Veterans with Binge Eating Disorder.
2. Determining Multiple Sclerosis Subtype from Electronic Medical Records.
3. Multiple Sclerosis Subtypes and Infections Resulting in a Hospitalization in the Veterans Health Administration.
4. Potential for Early Pharmacoepidemiologic Studies and Monitoring Intake of a Biologic Treatment Using an Electronic Health Records Database Prior to Assigned J-Code.
5. Characterization of Patients with ANCA-Associated Vasculitis by Subtype in the Veterans Affairs Database.
6. Conformity Between Protocol Eligibility Criteria For Electronic Patient Identification: A Comparison of Clinical Trials.
7. Utilization of New Diagnosis Codes for Basal Cell Carcinoma in 2 Large Nationwide EHR Databases.
8. Standard Method for Assessment of Electronic Health Record (EHR) Data Sources for Pharmacoepidemiology.
To view these posters in detail or others presented by Anolinx™ researchers, scientists and collaborators, please follow the link anolinx.com/publications.
Anolinx™ is a data-driven clinical research and clinical trials recruitment company that digs deep into electronic health records to significantly improve the clinical trials process. Its access to current real-world healthcare data and advanced analytics allow for quicker identification of patients, with greater precision.